May 30, 2026 — RNews

#neuroprotection — Saturday, May 30, 2026 (2 items)

hot top new

0		💬 0	Efficacy and safety of intravenous prasinezumab in individuals with early-stage Parkinson's disease on stable symptomatic monotherapy (PADOVA): a phase 2b, multicentre, randomised, double-blind, placebo-controlled study. (linkinghub.elsevier.com)	Nikolcheva T … Bonni A The Lancet 2026-05-30	#clinical trial #immunotherapy #neurodegeneration #neuroprotection
0		💬 0	Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials. (linkinghub.elsevier.com)	Cummings JL … Feldman HH The Lancet 2026-05-30	#clinical trial #neurodegeneration #neuroprotection #pharmacotherapy #dementia